Analyst Price Targets — HCA
Latest News for HCA
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
HCA Healthcare is upgraded to "Buy" after recent underperformance, with shares now reflecting payer mix and policy headwinds. HCA's Q2 results beat expectations due to a $400 million one-time Medicaid payment, masking underlying margin compression from a worsening payer mix. Guidance was cut, with 2026 EPS now seen at $29–$30 (excluding windfall: ~$28), and free cash flow run-rate at ~$6 billion, reflecting…
HCA Healthcare Inc.'s (NYSE:HCA) stock is trading lower on Tuesday after cutting its fiscal 2026 earnings guidance from $29.10-$31.50 to $28.70-$30.50.
HCA Healthcare stock falls after the hospital chain operator lowers its full-year profit outlook as uninsured patients rise in the second quarter.
The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.